Affitech, IBC Generium deal

Affitech's Affitech Research A/S subsidiary and IBC Generium signed a binding term sheet to grant IBC a license to Affitech's Molecular Based Antibody Screening (MBAS) technology and phage antibody libraries. Affitech will receive an upfront payment and will be eligible for payment upon successful transfer of the technology, plus annual license fees. IBC has exclusive rights to commercialize products developed using the technology, while Affitech would also be eligible for milestones and royalties on the products developed by IBC using MBAS. ...